Zelgen Biopharmaceuticals plans Hong Kong H-share listing, strategic realignments

Suzhou Zelgen Biopharmaceuticals announced on November 14, 2025, its intention to issue H-shares and list them on The Stock Exchange of Hong Kong Limited to support its international strategy and enhance competitiveness. This move, approved by the board, is subject to shareholder and regulatory approvals. Credit Suisse (Hong Kong) will serve as its auditor for the H-share offering and listing.

In a related development, the company is reallocating approximately 21,500.00 yuan from its "New Drug R&D Project" by reducing investments in two Jacotinib clinical trials by 9,200.00 yuan and 12,300.00 yuan, respectively. These funds will be redirected to a new ZG006 clinical trial for small cell lung cancer (16,500.00 yuan) and to supplement working capital (5,000.00 yuan). The company also plans to delist its US subsidiary, Gensun Biopharma Inc., which holds $588.8838 million in registered capital, to optimize its internal management structure and reduce R&D costs.

Further governance changes include the resignation of Mr. Yuan Hongchang as an independent director, due to personal reasons, which necessitates the election of Mr. Guo Bing as a new independent director. Mr. Guo Bing, born in 1973, holds a doctorate and has extensive experience in corporate management.